Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan-610041, P.R. China.
Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan-610041, P.R. China.
Curr Stem Cell Res Ther. 2024;19(1):55-62. doi: 10.2174/1574888X18666230118122256.
The novel pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), a serious challenge for human health. In severe cases, patients suffer from acute respiratory distress syndrome even organ failure, usually owing to the dysregulated immune response and widespread inflammation. Considering that there is no known cure for COVID-19 despite the increased morbidity and mortality rate of COVID-19, modalities targeting immunity and inflammation may be promising therapeutics against COVID-19. Mesenchymal stem cells (MSCs) possessing immunomodulatory, anti-inflammatory, anti-apoptotic, and antiviral properties, can be of potential benefit to a subset of severe and critically ill patients with COVID-19. In the present study, we described the underlying mechanisms of MSCs therapy and provided a thorough research study on the recent clinical trials of MSCs for SARS-CoV-2 infection.
新型致病严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）可引起 2019 年冠状病毒病（COVID-19），这对人类健康构成严重挑战。在严重情况下，患者会出现急性呼吸窘迫综合征甚至器官衰竭，这通常是由于免疫反应失调和广泛的炎症。尽管 COVID-19 的发病率和死亡率有所增加，但目前尚无针对 COVID-19 的已知治愈方法，因此针对免疫和炎症的方法可能是治疗 COVID-19 的有前途的疗法。间充质干细胞（MSCs）具有免疫调节、抗炎、抗凋亡和抗病毒特性，可能对 COVID-19 重症和危重症患者中的一部分具有潜在益处。在本研究中，我们描述了 MSCs 治疗的潜在机制，并对 MSCs 治疗 SARS-CoV-2 感染的最新临床试验进行了全面研究。
